Viral vaccines and viral vectors used in biotherapeutic applications carry the risk of microbial contamination, which must be addressed.
Priyabrata Pattnaik
Advertisement
Priyabrata Pattnaik, PHD, is head of biologics operations-Asia Pacific, MilliporeSigma.
Articles by Priyabrata Pattnaik
Advertisement
Latest Updated Articles
Ensuring Viral Safety of Viral Vaccines and VectorsPublished: September 1st 2018 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
2
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
3
Everything to Know About Cell and Gene Therapy in 2025
4
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
5
